ABVC · Abvc Biopharma, Inc. · Analyst Estimates
$0.93
-0.05 (-5.09%)
At close · Oct 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“For the six months ended June 30, 2026, the Company reported net loss of $2,500,418. As of June 30, 2026, the Company's working capital deficit was $5,282,776. In addition, the Company had net cash outflows of $1,138,656 from operating activities for the six months ended June 30, 2026. These conditions give rise to substantial doubt as to whether the Company will be able to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$29.29M
Shares
26.65M
Volume · Oct 6
67.74K
Avg daily vol (3M)
131.85K
Analyst Estimates
Compare analyst forecasts for Abvc Biopharma, Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.
Captured 2026-09-18 05:00 UTC · Publication dates shown per estimate · 4 metric / period groups
FY ending 2023-12-31
| Metric | Low | Average | High | Analyst count |
|---|---|---|---|---|
|
Revenue
Publication date not stated |
0
|
0
|
0
|
— |
|
Revenue
analysts
Publication date not stated |
— | — | — |
0
|
Q ending 2023-06-30
| Metric | Low | Average | High | Analyst count |
|---|---|---|---|---|
|
Revenue
Publication date not stated |
0
|
0
|
0
|
— |
|
Revenue
analysts
Publication date not stated |
— | — | — |
0
|